ONCOTELIC THERAPEUTCS INC - OTLC STOCK NEWS

Oncotelic Therapeutics (OTCQB:OTLC) announced its participation at the Precision in Drug Discovery & Preclinical Summit in San Diego. Dr. Wen-Han Chang, Nanomedicine Sr. Manager, and Dr. Tara Zand, Research Scientist, presented the company's Sapu Bio pipeline of TGFB2 therapeutics. Both scientists are focused on developing treatments for pancreatic and brain cancers through nanomedicine and precision drug development approaches.

Oncotelic Therapeutics (OTCQB:OTLC) announced that Product Manager Scott Myers will present at the 2nd Global Summit on Artificial Intelligence. The digital summit focuses on 'Pioneering the New Era: Advancing Global Development through Artificial Intelligence.' Myers will discuss the PubMed Corpus Builder, part of the Orion AI Suite developed by Sapu Bioscience

The PubMed Corpus Builder uses AI and LLMs to create comprehensive document corpora from the PubMed Central Database. It generates multiple search queries, downloads documents, and refines selection using vector search. The tool can identify documents with specific types of graphs and interpret them using multimodal technology. This system significantly accelerates the research process, allowing scientists to efficiently filter through hundreds of documents in minutes.

Oncotelic Therapeutics (OTCQB:OTLC) announced that its CEO, Dr. Vuong Trieu, will present at the 20th Annual Congress of International Drug Discovery Science & Technology in Budapest, Hungary, from June 17-19, 2024. Dr. Trieu will discuss OT-101, an antisense therapeutic targeting TGFB2, currently in phase 3 clinical trials for pancreatic cancer and glioblastoma. The presentation will also cover the potential of OT-101 in treating colorectal cancer (CRC), supported by clinical and bioinformatic analyses. Preliminary results indicate that OT-101 might prolong progression-free survival in CRC patients, particularly those with low TGFB2 and TGFM6 expression. Further analysis reveals a significant survival benefit in patients with low TGFB2/TGM6 expression. These findings could position OT-101 as a promising treatment for CRC, melanoma, and pancreatic cancer.

Oncotelic Therapeutics (OTCQB: OTLC) announced on May 30, 2024, that its CEO, Dr. Vuong Trieu, will attend the BIO International 2024 meeting in San Diego from June 3-6. The BIO International Convention is the largest biotech industry event, attracting over 18,500 global leaders.

Oncotelic Therapeutics announced that Chief Clinical Officer Dr. Anthony Maida will present at the ASCO 2024 meeting. Key topics include:

1. A meta-analysis (abstract e16318) comparing serious adverse events, overall survival, and progression-free survival in pancreatic adenocarcinoma patients treated with modified FOLFIRINOX versus the standard regimen.

2. A study (abstract e14564) on the prognostic impact of TGFB2 mRNA levels, interferon-gamma receptor activation of IRF5, and CD276/B7-H3 expression in low-grade gliomas.

The presentation aims to provide insights into treatment outcomes and prognostic factors in these cancers.

Oncotelic Therapeutics, Inc (OTCQB:OTLC) will be presenting at the Biopharma Nexus Conference in San Diego 2024. Dr. Andy Hu, Nanomedicine Manager, will discuss Nanomedicines: Past, Present, Future. Dr. Hu is an expert in nanomedicine and biotherapeutics, aiming to enhance human health through innovative technologies.

Oncotelic Therapeutics, Inc. has agreed to sell its necroptosis cancer therapy assets to Mosaic ImmunoEngineering, Inc. The deal includes rights to Oncotelic's clinical-stage necroptosis cancer therapies and AI technologies for identifying immunotherapy combinations. Mosaic will issue $15 million in CPMV shares to Oncotelic, with potential for an additional $15 million in shares. The Mosaic team, experienced in bringing oncology products to market, will lead the development. Both companies will collaborate for a smooth transition of technologies. The agreement is subject to negotiation of definitive agreements and customary conditions.

Oncotelic Therapeutics, Inc (OTCQB:OTLC) announces a groundbreaking peer-reviewed publication on the therapeutic targeting of negative prognostic markers in low-grade gliomas. The study reveals the crosstalk between TGF-β and IFN signaling pathways, offering new strategies for treating gliomas and Systemic Lupus Erythematosus (SLE). The research identifies IRF5 as a common target for both diseases, potentially revolutionizing cancer treatment by modulating the immune response. Detailed analysis shows that low mRNA levels of TGFB2 and IFNGR2 result in improved survival for LGG patients, highlighting potential therapeutic targets for high-risk patients.

Oncotelic Therapeutics, Inc (OTLC) announces the initiation of the STOP-PC clinical trial for advanced pancreatic cancer. The trial focuses on OT-101, a novel RNA therapeutic targeting TGF-β2 to enhance immune response and inhibit tumor growth. Notably, OT-101 has shown promising single-agent activity with dose-dependent survival benefits. The Phase 2/3 trial will evaluate OT-101 in combination with mFOLFIRINOX compared to mFOLFIRINOX alone as second-line therapy for progressing cancer.